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Abstract
BACKGROUND: Hepatitis B is a global health problem carrying significant morbidity and mortality. Vaccination 
against hepatitis B virus (HBV) has been implemented with good effectiveness, but a small proportion of children do 
not respond well after complete routine vaccination. They are called non-responders and are at higher risk for HBV 
infection.
AIM: The objective of the study was to determine the effect of revaccination with recombinant HBV vaccine containing 
higher antigen concentration in non-responder children.
METHODS: A prospective study was conducted from January 2018 until December 2019. Inclusion criteria were 
children aged 9–15 months and had three doses of recombinant HBV at 0, 1, and 6 months old. Exclusion criteria 
were the presence of acute or chronic hepatitis B and conditions which alter immune function and immunosuppressant 
medications consumption. Demographic and clinical characteristics were gathered from each subject along with 
serum HBsAb titer examination. Subjects with serum anti-hepatitis B surface antigen (HBsAb) titer of <10 IU/L were 
classified into non-responders and underwent revaccination with 3 doses of vaccine containing 20 µg HBsAg. The 
revaccination series was repeated until all subjects showed seroconversion. After each series, repeated serum 
HBsAb titer measurements were conducted.
RESULTS: A total of 400 children were enrolled in this study with a mean age of 12.1 (SD 2.64) months. Subjects 
were dominated with females (54.0) and normal nutritional status (79.0). The rate of non-responsiveness was 
9.0%. Of all non-responders, 88.9% experienced seroconversion after the first revaccination series. After the third 
revaccination series, all subjects had serum HBsAb titer at the protective level.
CONCLUSION: Revaccination with recombinant HBV vaccine containing higher antigen concentration in non-
responder children is effective.
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Introduction
Hepatitis B still becomes a global health 
problem [1], [2]. Approximately 700 million adults 
have a history of prior hepatitis B and 120 million 
individuals are chronic hepatitis B surface antigen 
(HBsAg) carriers [3] It is estimated that 500,000 until 
1.2 million global deaths are related to hepatitis B. The 
prevalence of hepatitis B is higher in Asia compared 
to Europe [1]. Most developed countries have low 
hepatitis B endemicity and the transmission usually 
occurs horizontally from high-risk behaviors such 
as homosexual and drug user, blood transfusion, 
hemodialysis, and healthcare workers [2]. Vaccination 
is a preventive measure against hepatitis B virus 
infection and its complications [4], [5]. Vaccination 
against hepatitis B has been invented for a few decades 
ago. Universal childhood vaccination program involving 
this vaccine has greatly reduced the rate of both acute 
and chronic hepatitis B virus (HBV) infections [3], [6].
In the Netherlands, the vaccine should be 
administered at 0, 1, and 2 months [6]. In Indonesia, 
routine vaccination against hepatitis B utilizes a 
vaccine with a dose of 10 µg. Each person should 
receive a total of 3 doses at 0, 1, and 6 months [7]. 
Protective response following vaccination is marked 
by anti-hepatitis B surface antigen (HBsAb) titer of 
10 IU/L or higher [1], [6]. If someone has reached 
protective HBsAb level, he/she will have a lower risk 
of hepatitis B for at least 10 years [5]. It is reported 
that 5–30% person does not have a protective 
response after routine vaccination. They are known 
as non-responders [3], [4], [6], [8] while those who 
had HBsAb titer between 10 and 100 IU/L are called 
low responders [3], [4], [8]. Another literature defines 
non-responder as a subject who is unable to produce 
protective HBsAb titer despite receiving 2 series of 
HBV vaccination after acute or chronic hepatitis B have 
been excluded and low responder as a non-responder 
who experiences seroconversion after the second 
series of HBV vaccination [7]. Non-responders are at 
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high risk of HBV infection and its complications. They 
also become sources of hepatitis B spreading [6].
Repeated vaccination or revaccination is 
recommended for non-responders to overcome 
the risks [6], [7], [9]. There are several methods in 
conducting revaccination including giving additional 
dose at varying times, repeating standard schedule, 
administering a double dose, giving vaccine with higher 
antigen content, and administering vaccine through the 
intradermal route [5]. Our study aimed to determine the 
effect of revaccination with HBV vaccine containing 
higher antigen concentration in non-responder children.
Methods
This prospective study was conducted in 
Universitas Sumatera Utara Hospital and several 
private clinics in Medan, Indonesia from January 
2018 until December 2019. Subjects were children 
aged 9–15 months previously vaccinated with three 
doses of recombinant HBV vaccine according to the 
governmental program at 0, 1, and 6 months old. 
Exclusion criteria were children suffering from acute 
or chronic hepatitis B, consuming immunosuppressant 
medications, and having conditions which alter immune 
function such as acquired immune deficiency syndrome. 
Subjects were obtained using a total sampling method. 
Demographic and clinical characteristics were gathered 
from each subject. Determination of serum HBsAb titer 
was conducted using HBsAb commercial kit (Diapro, 
Italy) according to the manufacturer’s instruction. A 
venous blood sample was drawn and centrifugated to 
obtain the serum. Sera were kept at a temperature of 
−20°C until the procedure was performed. Subjects 
with serum HBsAb titer of <10 IU/L were classified into 
non-responders and further underwent revaccination 
with 3 doses of Engerix-B (GlaxoSmithKline) containing 
20 µg HBsAg at the following 0, 1, and 6 months. The 
revaccination series was repeated until all subjects 
showed seroconversion into the protective level. After 
each series, repeated serum HBsAb titer measurements 
were conducted. Data analysis was done with statistical 
software and the results will be presented in tables. This 
study was approved by the Health Research Ethical 
Committee, Medical School, Universitas Sumatera 
Utara.
Results
A total of 400 children fulfilled the inclusion 
criteria of this study. Mean age of subjects was 12.1 (SD 
2.64) months. Gender distribution was almost similar 
with slight female domination. A total of 79% subject 
had a normal nutritional status. The amount of non-
responders in this study was 36 (9%) children (Table 1). 
The 36 children followed revaccination program, as 
mentioned above.
Table 1: Baseline characteristics of subjects
Characteristics n=400
Mean age, months (SD) 12.1 (2.64)
Gender, n (%)
Male
Female
184 (46.0)
216 (54.0)
Nutritional status, n (%)
Underweight
Normal
Overweight
48 (12.0)
316 (79)
36 (9)
Immune response, n (%)
Non-responder
Protective level
36 (9.0)
364 (91.0)
SD: Standard deviation.
Of 36 non-responder children who underwent 
the first series of revaccination, 32 children achieved 
protective serum HBsAb titer. The rest 4 children 
followed the second series of revaccination. In the end 
of the series, serum HBsAb titer of all subjects was in 
protective level (Table 2).
Table 2: Immune response of subjects after the first and second 
series of revaccination
Immune response After the first series of 
revaccination
After the second series of 
revaccination
Non-responder, n (%) 4 (11.1) 0 (0.0)
Protective level 32 (88.9) 4 (100.0)
Discussion
Hepatitis B is a disease caused by hepatitis B 
virus infection which may progress to chronic disease 
and cause severe complications such as liver cirrhosis 
and hepatocellular carcinoma [2], [10], [11]. Vaccine 
against HBV was introduced in the early 1980s and 
WHO urged all countries to involve the vaccine into 
their immunization programs [1], [8], [11]. All HBV 
vaccines contain HBsAg, a protein from hepatitis B 
virus envelope. Hepatitis B surface antigen is expected 
to activate lymphocyte cells through antigen-presenting 
cells and preserve immunity in a longer period. There 
are 2 types of HBV vaccine: Plasma-derived vaccine 
and recombinant vaccine. Adjuvants are added 
to improve the immunogenicity of the vaccine [8]. 
Complete schedule of vaccination against HBV (3 or 
4 doses according to regional protocol) gives safe and 
effective protection. However, a particular subject does 
not produce protective HBsAb even after complete 
vaccination [10]. A study from Iran involving children 
and adolescents aged 6–18 years reported that the 
response to HBV vaccine was only 38.5% [1]. Data 
from Bangladesh reported that 88.67% vaccinated 
individuals had protective HBsAb titer [2]. About 4% 
vaccinated newborns with HBV vaccine does not reach 
protective antibody level [1], [12] where 0.4% does not 
respond even after revaccination while the rest 3.6% 
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achieves protective antibody titer [12]. The result in our 
study was similar to the literature above. As many as 
91% children receiving routine hepatitis B vaccination 
reached protective serum HBsAb titer. The rate of non-
responder in our study was 9.0%.
Poor response toward vaccination is 
associated with male gender, advanced age, 
obesity, smoking, genetic predisposition, type 
of vaccine, number of injection, subcutaneous 
administration of vaccine, adjuvant used, and vaccine 
handling [2], [4], [6], [7], [9]. Low ratio of T helper cell 
compared to T cytotoxic cell, high ratio of natural killer 
to T killer cell, and psychosocial stress shortly after 
vaccination is other risk factors for unsatisfied respond 
toward vaccination [10]. Older age is associated with 
suboptimal response toward HBV vaccine due to 
waning of immunity [1], [8]. Subcutaneous injection 
may decrease antigen-presenting cell’s activation and 
inhibit antigen presentation to lymphocytes [7]. Obesity 
is associated with decreased number and function of 
lymphocytes [9]. Higher body weight also hampers 
immune response from decreased vaccine absorption 
in adipose tissue [1]. A case report described that obese 
women who had received six doses of HBV vaccine failed 
to achieve protective HBsAb titer until she underwent 
gastroplasty Roux-en-Y gastric bypass to overcome her 
obesity. She needed 3 additional doses after the surgery 
to experience seroconversion [9]. Genetic susceptibility 
in HBV vaccine non-responsiveness is associated with 
HLA haplotypes such as DRB1*3, DRB1*7, DRB1*14, 
DQB1*0604, DQA1*0102, and DRB1*1302 [8], [11]. 
The role HLA-C4A locus in the responsiveness toward 
HBV vaccination is hypothesized. The presence of 
C4AQ0 allele is associated with non-responsiveness to 
HBV vaccination even in the absence of DRB1*0301, 
DQB1*02, or DRB1*0701. The allele is expected to 
impair the function of complement and further antibody 
response to T-dependent antigen. This condition is 
observed in both adults and neonates [12]. Other 
literatures stated that the presence of HLA-DR2, 
HLA-DR3, HLA-DR7, HLA-DR14, and HLA-B8 was 
the genetic–associated risk factor for poor vaccination 
response [2], [4], [10]. There was no significant gender 
predisposition in our study. All subjects were also aged 
<2 years. Most subjects had a normal nutritional status.
A study evaluated revaccination response 
in non-responder adults after receiving 3 doses of 
Engerix-B or HBVaxpro-10. They were revaccinated 
by either Twinrix (GlaxoSmithKline), HBVaxPro40 
(Merck Sharp & Dohme), or Fendrix (GlaxoSmithKline) 
compared to Engerix-B (GlaxoSmithKline). Statistical 
analysis showed that the proportion of responders in 
HBVaxPro40 and Fendrix groups was higher compared 
to Engerix-B group as the control. HBsAb titer was also 
higher in both groups compared to control. This was 
probably caused by a higher antigen dose in Fendrix 
and HBVaxPro40. More potent adjuvant used in both 
vaccines might also contribute to higher response [6]. 
Clemens et al. studied a proportion of low- and non-
responder adults after hepatitis B vaccination at 0, 
1, and 6 months. They administered booster vaccine 
(Engerix-B, SmithKline Beecham Biologicals) with 
higher HBV antigen dose (20 µg) at 2 months interval 
until the subjects had HBsAb titer of ≥100 mIU/mL. 
After the 3rd booster, all non-responders had HBsAb 
titer of 100 mIU/mL or higher [10]. Han et al. conducted 
a study in Guangdong and found that the rate of non-
responder and low responder of 3.1% and 28.9%, 
respectively, in infants receiving 3 doses of routine HBV 
vaccination. The routine HBV vaccine used contains 
5 µg antigens. Revaccination was conducted using 3 
doses of HBV vaccine with a higher content of antigen. 
All of the non-responders achieved low responder 
and responder status after revaccination [3]. The 
literature above confirmed the result of our study. We 
found that revaccination with HBV vaccine containing 
higher antigen concentration resulted in better immune 
response in non-responder children. However, we 
needed 2 series of revaccination to achieve serum 
HBsAb titer of ≥10 IU/L in all subjects who previously 
were non-responders.
In contrast with our study, Joukar et al. showed 
that a double dose of vaccine was more effective 
compared to a single dose in the early revaccination 
program. However, after the third dose of vaccine, both 
single and double dose gave similar effectiveness. All 
non-responsive subjects experienced seroconversion 
after the third dose of revaccination [5]. Their result 
was supported by several studies. A study in Bandung, 
Indonesia, showed that 5.5% of 144 children were 
non-responders. After receiving the second series 
of revaccination, all of them had protective HBsAb 
titer [7]. Cardell et al. administered 3 doses of combined 
hepatitis A and B vaccine as a revaccination program. 
After the third dose of vaccination, 95% non-responders 
produced a protective level of HBsAb [11]. Ahad 
et al. reported that booster HBV vaccine significantly 
increased HBsAb titer [2].
Intradermal administration of HBV vaccine 
is suggested to be more effective in particular 
populations, including non-responders. Intradermal 
administration also requires less amount of antigen 
to induce protective immunity and may cut the cost 
of immunization [4]. This statement is supported by 
Cardell et al. Their study found that administration of 
hepatitis B vaccine intradermally resulted in antibody 
production to a protective level in 68.3% study 
subjects. Administration of additional 1 booster vaccine 
increased the percentage to 88.9% [11]. However, the 
effectiveness of intradermal administration of HBV 
vaccine needs further study before being applied to 
non-responders [4].
The limitation of our study was that we could 
not rule out confounding factors non-responsiveness 
status such as genetic predisposition and vaccine 
handling. We also did not conduct follow-up after 
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revaccination series to rule out the factors that might 
contribute to vaccination response. However, this was 
the first study in our region regarding the management 
of HBV vaccine non-responder children. In conclusion, 
revaccination with recombinant HBV vaccine containing 
higher antigen concentration in non-responder children 
is effective.
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